{"id":443755,"date":"2021-09-21T00:00:00","date_gmt":"2021-09-21T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0021-2021-biopharma-small-cell-lung-cancer-current-treatment-physician-insights-us-2021\/"},"modified":"2026-03-31T10:42:31","modified_gmt":"2026-03-31T10:42:31","slug":"cutron0021-2021-biopharma-small-cell-lung-cancer-current-treatment-physician-insights-us-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0021-2021-biopharma-small-cell-lung-cancer-current-treatment-physician-insights-us-2021\/","title":{"rendered":"Small-Cell Lung Cancer | Current Treatment: Physician Insights | US | 2021"},"content":{"rendered":"<p>Treatment of small-cell lung cancer (SCLC) has long been dominated by chemo(radio)therapy, but the standard of care for first-line extensive-stage SCLC recently changed, following the FDA\u2019s approval of Roche \/ Genentech\u2019s Tecentriq (2019) and AstraZeneca\u2019s Imfinzi (2020); both PD-L1 inhibitors are prescribed in combination with chemotherapy. The FDA approvals of PharmaMar \/ Jazz Pharmaceuticals\u2019 Zepzelca and G1 Therapeutics\u2019 Cosela have also expanded the treatment options for patients with extensive-stage SCLC. This content will explore U.S. physicians\u2019 prescribing behavior when treating SCLC.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are physicians\u2019 standard treatment practices for limited- and extensive-stage SCLC?<\/li>\n<li>What is the uptake of PharmaMar \/ Jazz Pharmaceuticals\u2019 Zepzelca in patients with metastatic SCLC who have progressed on or after prior platinum-based therapy?<\/li>\n<li>How do drug-treatment rates vary across limited- and extensive-stage SCLC populations, according to the line of therapy?<\/li>\n<li>What are the key drivers and obstacles determining current prescribing of immune checkpoint inhibitors for extensive-stage SCLC? How do physicians differentiate between Tecentriq and Imfinzi in the first-line extensive-stage SCLC setting?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em><strong>Current Treatment: Physician Insights<\/strong><\/em> provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Primary research:<\/strong><strong> <\/strong> Survey of 100 medical oncologists in the United States fielded in June 2021<\/p>\n<p><strong>Key drugs:<\/strong><strong> <\/strong> Cosela, Imfinzi, Tecentriq, Zepzelca<\/p>\n","protected":false},"template":"","class_list":["post-443755","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-small-cell-lung-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/443755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/443755\/revisions"}],"predecessor-version":[{"id":444073,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/443755\/revisions\/444073"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=443755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}